417 related articles for article (PubMed ID: 3142085)
1. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
2. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
Kluft C; Jie AF; Rijken DC; Verheijen JH
Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
[TBL] [Abstract][Full Text] [Related]
3. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
Urano T; Sumiyoshi K; Pietraszek MH; Takada Y; Takada A
Thromb Haemost; 1991 Oct; 66(4):474-8. PubMed ID: 1796399
[TBL] [Abstract][Full Text] [Related]
4. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
Siegbahn A; Ruusuvaara L
Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
[TBL] [Abstract][Full Text] [Related]
5. [Problems in measuring parameters of the fibrinolytic system: circadian rhythm of tissue-type plasminogen activator and plasminogen activator inhibitor].
Köhler M; Miyashita C
Klin Wochenschr; 1988; 66 Suppl 12():62-7. PubMed ID: 3126347
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.
Nicoloso G; Hauert J; Kruithof EK; Van Melle G; Bachmann F
Thromb Haemost; 1988 Apr; 59(2):299-303. PubMed ID: 3133812
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
8. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
10. [Decreased fibrinolytic capacity in coronary patients by increased plasminogen activator inhibitor activity].
Ihnken K; Speiser W; Müller-Berghaus G; Beyersdorf F; Schlepper M; Satter P
Helv Chir Acta; 1992 Jan; 58(4):503-8. PubMed ID: 1582860
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor activity in bacterial infection.
Páramo JA; Fernández Diaz FJ; Rocha E
Thromb Haemost; 1988 Jun; 59(3):451-4. PubMed ID: 3142082
[TBL] [Abstract][Full Text] [Related]
12. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma.
Dooijewaard G; de Boer A; Turion PN; Cohen AF; Breimer DD; Kluft C
Thromb Haemost; 1991 Jan; 65(1):82-6. PubMed ID: 1902597
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activators t-PA, u-PA and its inhibitor (PAI) in normal males and females.
Koh SC; Yuen R; Viegas OA; Chua SE; Ng BL; Sen DK; Ratnam SS
Thromb Haemost; 1991 Nov; 66(5):581-5. PubMed ID: 1803623
[TBL] [Abstract][Full Text] [Related]
14. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice.
Lijnen HR; Moons L; Beelen V; Carmelie P; Collen D
Thromb Haemost; 1995 Oct; 74(4):1126-31. PubMed ID: 8560424
[TBL] [Abstract][Full Text] [Related]
15. Fibrinolysis and coagulation in patients with infectious disease and sepsis.
Philippé J; Offner F; Declerck PJ; Leroux-Roels G; Vogelaers D; Baele G; Collen D
Thromb Haemost; 1991 Mar; 65(3):291-5. PubMed ID: 1904655
[TBL] [Abstract][Full Text] [Related]
16. Release pattern of the vascular plasminogen activator and its inhibitor in human postvenous occlusion plasma as assessed by a spectrophotometric solid-phase fibrin-tPA activity assay.
Anglés-Cano E; Boutière B; Arnoux D; Masson C; Contant G; Benchimol P; Sampol J
Thromb Haemost; 1987 Oct; 58(3):843-9. PubMed ID: 3124285
[TBL] [Abstract][Full Text] [Related]
17. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
18. Impaired fibrinolysis in obstructive jaundice--evidence from clinical and experimental studies.
Colucci M; Altomare DF; Chetta G; Triggiani R; Cavallo LG; Semeraro N
Thromb Haemost; 1988 Aug; 60(1):25-9. PubMed ID: 3142090
[TBL] [Abstract][Full Text] [Related]
19. Increased plasminogen activator inhibition levels in malignancy.
de Jong E; Knot EA; Piket D; Iburg AH; Rijken DC; Veenhof KH; Dooijewaard G; ten Cate JW
Thromb Haemost; 1987 Apr; 57(2):140-3. PubMed ID: 3110994
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
